Phase 1 Clinical Data Demonstrate Dose-Proportional PK, No Dose-Limiting Toxicities Through Four Dose Levels, and Concordance with Preclinical ...

Simulations Plus, Inc., a company vested in AI-accelerated drug development, reports the launch of a technical collaboration ...

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and ...

Investing.com -- Simulations Plus (NASDAQ:SLP) shares surged 28% following the announcement of a technical collaboration with ...

Veterinarians and producers are using science-based tools like FARAD, PBPK modeling, and targeted treatment protocols to prevent drug residues from entering the food supply. These approaches provide ...

Certara’s updated fair value estimate has shifted from US$8.99 to US$8.71, a small reset that still sits in the same broad price target zone as recent Street moves toward roughly US$8 to US$10. Those ...

Time finding study of chronomodulated irinotecan (I), fluorouracil (F), leucovorin (L) and oxaliplatin (O) (chronoIFLO) against metastatic colorectal cancer: Results from randomized EORTC 05011 trial ...

Suraxavir marboxil (GP681) is an orally available prodrug that is converted in vivo to the active metabolite GP1707D07, a PA-targeting antiviral against influenza. Because GP1707D07 is primarily ...

Objectives: Pharmaceutical cocrystals are typically formed by combining an active pharmaceutical ingredient with a coformer to enhance drug solubility, stability and dissolution, thereby improving ...

RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator ...